The US firm’s vaccine candidate is one of at least four Covid vaccines being trialled in South Africa, along with candidates being developed by Novavax, AstraZeneca and Pfizer
Topics
Coronavirus | Johnson & Johnson | Coronavirus Vaccine
Reuters | Cape Town
Last Updated at December 15, 2020 01:53 IST
South Africa’s pharmaceutical regulator SAHPRA said on Monday it has received its first application to register a Covid-19 vaccine from Johnson & Johnson.
“As of today we have received one application, this was received on Thursday evening from J&J, and we started the review process,” said Boitumelo Semete, chief executive of the South African Health Products Regulatory Authority (SAHPRA).
J&J did not immediately respond to an emailed request for comment.
The US firm’s vaccine candidate is one of at least four Covid vaccines being trialled in South Africa, along with candidates being developed by Novavax, AstraZeneca and Pfizer.
Semete told a news conference the regulator would focus on “safety, quality and efficacy” of any coronavirus vaccine used in the country of around 58 million as it fast-tracks vaccine approvals.
South Africa, which officially entered a second wave of infections last week, has more than 860,000 infections and 23,000 deaths, and is the worst-hit country in the continent.
No child in Astra trial
Drugmaker AstraZeneca has removed children from a mid-to-late stage trial of its Covid-19 vaccine in Britain, clinical trial registers in the United States showed on Monday.
The trial of more than 12,000 participants previously included children above the age of five with the consent of their parents. However, the trial data under the US National Library of Medicine was updated on December 10 to remove the sub-group including children. Reuters
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
First Published: Tue, December 15 2020. 01:50 IST
read the full story about J&J has applied to South Africa for registering coronavirus vaccine
#theheadlines #breakingnews #headlinenews #newstoday #latestnews #aajtak #ndtv #timesofindia #indiannews